US 11542242
Substituted piperazines as selective HDAC1,2 inhibitors
granted A61PA61P35/00A61P35/02
Quick answer
US patent 11542242 (Substituted piperazines as selective HDAC1,2 inhibitors) held by Regenacy Pharmaceuticals, Inc. expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Regenacy Pharmaceuticals, Inc.
- Grant date
- Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61P, A61P35/00, A61P35/02, A61P7/00